1.59“Know-How” means all proprietary information, know-how and data, including trade secrets, Inventions (whether patentable or not), discoveries, methods, specifications, processes, procedures, formulas, expertise, technology, data (including non-clinical, pre-clinical and clinical data), documentation, materials, and results (including pharmacological, toxicological, biological, chemical, physical, safety and Manufacturing data and results), analytical and quality control data and results, Manufacturing techniques, Regulatory Filings and other technical information. “Know-How” excludes in any event any Patents.
1.60“Law” means any law, statute, rule, regulation, order, judgment or ordinance having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision.
1.61“Licensed Capsid” means: (a)(i) a Capsid Candidate for which Pfizer has exercised the applicable Option in accordance with Section 2.4 and paid the applicable Option Exercise Fee; or (ii) any Substitute Capsid that Pfizer has designated as a replacement therefor in accordance with Section 2.5 and (b) any Functionally Equivalent Variant of the Capsid Candidate or Substitute Capsid described in (a)(i) or (a)(ii) as applicable.
1.62“Licensed Capsid Patent” means, collectively, any Capsid Patent that Covers any Licensed Capsid, but excluding any Licensed Product Patent.
1.63“Licensed Field” means all indications for therapeutic, diagnostic and prophylactic human and veterinary use.
1.64“Licensed Product” means a product comprising both of the following: (a) a Licensed Capsid; and (b) the specific Pfizer Transgene for which Pfizer exercised its Option for such Licensed Capsid, as identified in Pfizer’s Option Exercise Notice.
1.65“Licensed Product Patent” means, collectively, any Patent Controlled by Pfizer at any time during the Term with claims directed to the combination of a Licensed Capsid and a Pfizer Transgene together or any method of use directed to such combination.
1.66“Litigation Conditions” has the meaning set forth in Section 9.4.
1.67“Losses” has the meaning set forth in Section 9.1.
1.68“Major Market Country” means the United Kingdom, France, Germany, Italy, Spain and Japan.
1.69“Manufacture” means activities directed to manufacturing, processing, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, testing, and release, shipping, or storage of any pharmaceutical or biologic product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including process development, qualification, and validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, product characterization, and stability testing. “Manufacturing” has correlating meaning.
1.70“[**] Transgene” means a [**].